10:34 AM EST, 02/20/2025 (MT Newswires) -- Trinity Capital ( TRIN ) said Thursday it has committed $15 million in growth capital to medical device company Cagent Vascular.

Cagent Vascular is a developer of serration technology that treats peripheral artery disease. The company's flagship product helps improve angioplasty procedures.

The funding adds to the $45 million of equity financing led by US Venture Partners last year, Trinity Capital ( TRIN ) said.

Price: 16.05, Change: -0.16, Percent Change: -0.99